Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Health Ministry Approves 28 Products including Oblean, Kadcyla
September 26, 2013
- Discussions on Reform of the High-cost Healthcare Benefit System on the Horizon; Will It Be Possible to Reduce Drug Copayments?
September 25, 2013
- Japan Needs Generic Drug Makers that Can Compete in the Global Market: Director Jo of EAD
September 25, 2013
- Regulatory Reform Council Sets Out Policies to Monitor Ministries’ Deregulation Efforts
September 24, 2013
- MHLW to Introduce E2B (R3) Format in April 2016
September 24, 2013
- FTC’s Legal Intervention in Diovan Issue Possible, but Only with New Facts: Lawyer
September 20, 2013
- MHLW Requests Revision of Package Inserts for Losartan, Celecoxib, 9 Other Drugs
September 19, 2013
- MHLW Plans to Establish Ethics Committee Certification System to Improve the Quality of Clinical Research
September 18, 2013
- Diovan Scandal Undermined National Interests, Health Ministry Official Says
September 18, 2013
- Director Jo of EAD Urges Drug Makers to Go on the Offensive
September 18, 2013
- PAFSC Second Committee Supports Hepatitis C Treatment Simeprevir, Plasma Fraction Product Hizentra
September 17, 2013
- Intussusception to Be Added to Adverse Reaction Section of Package Insert of RotaTeq
September 17, 2013
- Regulatory Reform Council Puts Off Concluding Discussion on Use of Clinical Intervention Study Data for Drug Applications
September 13, 2013
- Ms Ishii of LDP Calls for Permanent Extension of R&D Tax Credit for High-Level Investment
September 13, 2013
- MHLW Lifts Certified Oncologist Requirement for Tarceva
September 12, 2013
- Medical Expenditure for Dispensing Totaled 6,590.2 Billion Yen in FY2012; Generic Drug Ratio 28.7%
September 12, 2013
- Diovan Panel Poised to Conduct Hearings with Ex-Novartis Employee, Authors
September 11, 2013
- Education Ministry Requests 950 Million Yen Budget for Promoting Generic Use at National University Hospitals
September 11, 2013
- PMDA Eyes Mandatory Electronic Filings for NDA Clinical Trial Data from FY2016
September 11, 2013
- Cabinet Secretariat’s TPP Headquarters Briefs Industry Organizations on 19th Round of TPP Talks
September 11, 2013
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…